ZYIL1 is a nucleotide‐binding oligomerization domain, leucine rich repeat and pyrin domain‐containing 3 (NLRP3) inflammasome inhibitor, which prevents NLRP3‐induced apoptosis‐associated speck‐like protein containing a caspase activation and recruitment domain oligomerization, thus inhibiting NLRP3 inflammasome pathway. We investigated the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ZYIL1 after single and multiple doses in healthy subjects. The subjects aged 18–55 years were enrolled in 2 different studies: single and multiple ascending dose. Blood/urine samples were collected at designated time points for pharmacokinetic and pharmacodynamic analysis. In the single‐ascending‐dose study, 30 subjects were enrolled (6 subjects each in 5 dose groups). One adverse event was reported during the study. ZYIL1 was well absorbed with median time to maximum plasma concentration at 1–1.5 hours. The exposures were dose proportional across the dose ranges. ZYIL1 is excreted as an unchanged form via the renal route. The mean elimination half‐life was 6–7 hours. In the multiple‐ascending‐dose study, 18 subjects were enrolled (6 subjects each in 3 dose groups). Eleven adverse events were reported by 6 subjects during the study. The accumulation index at steady state for area under the plasma concentration–time curve indicated that ZYIL1 has a marginal accumulation upon repeated dosing. Dose‐proportional exposure was observed across the dose ranges. All subjects showed >90% interleukin (IL)‐1β inhibition in all dose groups for both studies. Inhibition in IL‐1β and IL‐18 was observed throughout the 14 days of treatment in the multiple‐dose study. The safety profile, rapid absorption, marginal accumulation, and significant inhibition of IL‐1β and IL‐18 level support its development for the management of inflammatory disorders.
23 December 2023 in Naunyn-Schmiedeberg's Archives of Pharmacology
In India, approximately 33-46% people are obese which is a major risk factor to several non-communicable diseases. Amongst all existing treatment modalities, semaglutide injection is the proven most effective glucagon-like peptide-1 (GLP-1) receptor agonist for obesity, but high costs limit global accessibility. We report the Phase III trial evaluating the efficacy, safety and immunogenicity of a novel formulation of Semaglutide Injection in Indian patients with obesity. This multicentre, randomized, open-label, active-controlled trial enrolled 282 Indian adults with obesity (BMI ≥30 kg/m2) or overweight with comorbidities across geographically distributed 23 sites. Participants were randomized 2:1 to Semaglutide Injection 15 mg/3 mL (5 mg/mL) (Test Product; Zydus Lifesciences Ltd.) or Reference Semaglutide (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg) prefilled pen (Comparator Product; Novo Nordisk) for 24 weeks. Both arms followed an identical dose-escalation schedule from 0.25 mg to 2.4 mg once weekly. The primary endpoint was percentage weight change, with a non-inferiority margin of 5 percentage points. In terms of primary endpoint, Least squares mean (LSM) was −11.25% (Test Product) versus −11.50% (reference semaglutide), with a treatment difference of 0.25% (95% CI: −0.72 to 1.23), at the end of 24 weeks confirming non-inferiority. 90.4% and 58.0% of Test Product-treated participants achieved ≥5% and ≥10% weight loss, respectively. Adverse events were similar between groups (63.3% vs 62.8%), with predominantly mild gastrointestinal symptoms. No serious treatment-related adverse events, deaths, or discontinuations occurred. This novel formulation of Semaglutide Injection demonstrated therapeutic non-inferiority to the reference product with comparable safety and immunogenicity. Clinical Trials Registry–India (CTRI/2025/03/082620)
Background A novel fixed-dose combination of vilanterol 25-µg, umeclidinium 62.5-µg, and fluticasone furoate 200-µg (VIL-UME-FF) in dry powder inhaler (DPI) was developed by M/s. Zydus Healthcare Limited for managing persistent asthma. Methods In this phase 3, multicenter, parallel group, open-label, randomized trial, patients received either test (VIL-UME-FF DPI) or reference DPI (indacaterol 150-µg, glycopyrronium 50-µg, and mometasone furoate 160-µg; IND-GLY-MF DPI). The primary endpoint was change from baseline in trough forced expiratory volume-1 (FEV1) at week-12. Secondary endpoints included trough forced vital capacity (FVC), post-bronchodilator FEV1 and FVC, and asthma control test (ACT) score. Results A total of 258 participants (18-65 years) were enrolled (Test: 129; Reference: 129). The least square mean change in trough FEV1 at week-12 was 342.9 (21.3) ml for the test group and 327.6 (21.4) ml for the reference group (p=0.6141). The lower limit of 95% confidence interval for the difference between the groups was -44.19 ml, well-above the predefined non-inferiority margin (-150 ml). At week-12, trough FVC, post-bronchodilator FEV1 and FVC, and ACT scores were comparable between the study groups. Conclusion VIL-UME-FF DPI was non-inferior to IND-GLY-MF DPI in improving trough FEV1 and other efficacy parameters and was well-tolerated in Indian patients with persistent asthma.
2 December 2022 in Clinical Pharmacology in Drug Development